Explore how an innovative medicine moves from approval to patient access.
Selected market
Czechia
SÚKL conducts the administrative price and reimbursement proceeding. Highly innovative, orphan and centre medicines can use special routes, while health-insurance contracts and designated centres complete access.
EC/EMA or SÚKL
MAH/importer/insurer / SÚKL
SÚKL with procedure parties
SÚKL
SÚKL
8 decision nodes14 cited sources
For education only — not regulatory, pricing or legal advice.
